Safety of conventional systemic agents and biologic agents in the treatment of psoriasis

Journal of Cutaneous Medicine and Surgery

Volumn 13, Issue SUPPL. 2, 2009, Pages

  Bissonnette, Robert ^a   Ho, Vincent ^b   Langley, Richard G ^c  

^a INNOVADERM RESEARCH   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; AMIODARONE; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; CALCIUM CHANNEL BLOCKING AGENT; COTRIMOXAZOLE; CYCLOSPORIN; EFALIZUMAB; EMBREL; ERYTHROMYCIN; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; NICARDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PENICILLIN G; PHENOBARBITAL; PLACEBO; PROBENECID; SALICYLIC ACID; STELARA; TETRACYCLINE; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VERAPAMIL;

ABDOMINAL DISCOMFORT; ALOPECIA; ANAPHYLAXIS; ARTHRALGIA; ASEPTIC MENINGITIS; ATYPICAL MYCOBACTERIOSIS; BACKACHE; BIRTH DEFECT; BLOOD TOXICITY; BONE DISEASE; BRAIN PSEUDOTUMOR; CANADA; CARDIOVASCULAR DISEASE; CHEILITIS; CLINICAL TRIAL; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; DRY NOSE; DYSESTHESIA; ELECTROLYTE DISTURBANCE; FATIGUE; FIBROSIS; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; GINGIVA HYPERPLASIA; GOUT; HAIR LOSS; HAND TREMOR; HEMOLYTIC ANEMIA; HEPATITIS; HEPATITIS B; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPEROSTOSIS; HYPERPIGMENTATION; HYPERTENSION; HYPERTRICHOSIS; HYPERURICEMIA; HYPOMAGNESEMIA; INFECTION; INJECTION SITE REACTION; LIGAMENT CALCINOSIS; LIVER CIRRHOSIS; LIVER TOXICITY; LUNG DISEASE; LUNG FIBROSIS; LUNG TOXICITY; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALAISE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METABOLIC DISORDER; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; NEPHROTOXICITY; NEUROLOGIC DISEASE; NIGHT VISION; OPPORTUNISTIC INFECTION; PAPILLEDEMA; PAPULE; PARESTHESIA; PNEUMOCYSTIS PNEUMONIA; POLYRADICULONEUROPATHY; PORPHYRIA CUTANEA TARDA; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; REPRODUCTIVE TOXICITY; REVIEW; SALMONELLOSIS; SEIZURE; SIDE EFFECT; SKIN ABRASION; SKIN DISEASE; SKIN MANIFESTATION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TERATOGENICITY; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TUBERCULOSIS; UNITED STATES; URTICARIA; VISUAL DISORDER; VOMITING; XEROSIS;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL FACTORS; HUMANS; PSORIASIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 70449394214     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2009.00023     Document Type: Review

References (55)

1. Ho VC. The use of cyclosporine in psoriasis: a clinical review. Br J Dermatol 2004;150 Suppl 67:1-10.
2. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005;152:597-615.
3. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
4. Dutz JP, Ho V. Immunossuppressive agents in skin disorders. A comparative review. Clin Immunother 1996;5:268-93.
5. Ho VC, Zloty DM. Immunosuppressive agents in dermatology. Dermatol Clin 1993;11:73-85.
6. Stern DK, Tripp JM, Ho V, et al. The use of systemic immune moderators in dermatology: an update. Dermatol Clin 2005;23:259-300.
7. Mihatsch MJ, Belghiti D, Bohman SO. Kidney biopsies in control or cyclosporine A treated psoriatic patients. Br J Dermatol 1990;13:95-100.
8. Lowe N, Wieder JM, Rosenback A. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 1997;37:671-2.
9. Feutren G, Abeywickrama K, Friend D, et al. Renal function and blood pressure in psoriatic patients treated with cyclosporin A. Br J Dermatol 1990;122 Suppl 36:57-69.
10. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med 1992;326:1654-60.
11. Powles AV, Cook T, Hulme B, et al. Renal function and biopsy findings after 5 years treatment with low-dose cyclosporine for psoriasis. Br J Dermatol 1992; 128:159-65.
12. Young EW, Ellis CN, Messana JM, et al. A prospective study of renal structure and function in psoriasis patients treated with cyclosporine. Kidney Int 1994;46:1216-22.
13. Pei Y, Scholey JW, Katz A, et al. Chronic nephrotoxicity in psoriatic patients treated with low-dose cyclosporine. Am J Kidney Dis 1994;23:528-36.
14. Berth-Jones J, Henderson CA, Munro CS, et al. Treatment of psoriasis with intermittent short course cyclosporine (Neoral). A multicentre study. Br J Dermatol 1997; 136:527-30.
15. Faerber L, Braeutigam M, Weidinger G, et al. Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients. Am J Clin Dermatol 2001;2:41-7.
16. Ho VC, Griffiths CE, Albrecht G, et al. Intermittent short courses of cyclosporine (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol 1999;141:283-91.
17. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 year cohort study. J Invest Dermatol 2003;120:211-6.
18. Trexall [package insert]. Piomona (NY): Duramed Pharmaceuticals, Inc.; 2005.
19. Ho V, Cloutier RM, Griffiths W. Acitretin for the treatment of psoriasis and disorders of keratinization. Can J Dermatol 1995;7:757-65.
20. Soriatane [package insert]. Coral Gables (FL): Stiefel Laboratories, Inc.; 2008.
21. Aaronson DS, Lebwohl M. Review of therapy of psoriasis: the prebiologic armamentarium. Dermatol Clin 2004;22:379-88, viii.
22. van de Kerkhof PC. Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology. Dermatol Ther 2006;19:252-63.
23. Halverstam CP, Zeichner J, Lebwohl M. Lack of significant skeletal changes after long-term, low-dose retinoid therapy: case report and review of the literature. J Cutan Med Surg 2006;10:291-9.
24. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139: 719-27.
25. Amevive [package insert]. Deerfield (IL): Astellas Pharma US, Inc.; 2006.
26. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-13.
27. Krueger GE, Langley, RG, Leonardi C, et al. A human interleukine 12-23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92.
28. Viguier M, Richette P, Aubin F, et al. Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis. Arthritis Rheum 2008;58:1796-802.
29. Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 2006;5:197-209.
30. Raptiva [package insert]. South San Francisco (CA): Genentech; 2008.
31. Kwan JM, Reese AM, Trafeli JP. Delayed autoimmune hemolytic anemia in efalizumab-treated psoriasis. J Am Acad Dermatol 2008;58:1053-5.
32. Leonardi C, Menter A, Hamilton T, et al. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2008;158: 1107-16.
33. Leonardi CL, Toth D, Cather JC, et al. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology 2006;213:204-14.
34. European Medicines Agency Press Office. European Medicines Agency recommends suspension of the marketing authorization of Raptiva (efalizumab) [news release]. Available at: http://www.emea.europa.eu/ pressoffice/presshome.htm (accessed March 2, 2009).
35. US Food and Drug Administration. FDA Public Health Advisory. Updated safety information about Raptiva (efalizumab) [news release]. Available at: http://www.fda.gov/cder/drug/advisory/efalizumab.htm (accessed March 2, 2009).
36. Bala M, Guzzo C, Li S. Infliximab-associated serious adverse drug events are lower in psoriasis patients than in ulcerative colitis, Crohn's disease, and rheumatoid arthritis [AAD abstract P2739]. J Am Acad Dermatol 2007;56:AB184.
37. Burmester GR. Adalimumab safety profile in global clinical trials and reduction in standardized mortality ratio. Poster presented at American Academy of Dermatology Annual Conference; 2008 Feb 1-5; San Antonio, TX.
38. Gordon K, Gottlieb A, Giannini EH. Clinical trial safety data of events of interest in patients receiving etanercept (ENBREL) across approved indications. Poster presented at American Academy of Dermatology Annual Conference; 2008 Feb 1-5; San Antonio, TX.
39. Stone JH, Holbrook JT, Marriott MA, et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006;54:1608-18.
40. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 2007;13:1024-30.
41. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
42. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95.
43. Buchbinder R, Barber M, Heuzenroeder L, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 2008;59:794-9.
44. Remicade [package insert]. Malvern (PA): Centocor, Inc.; 2008.
45. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40.
46. de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223-31.
47. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new onset psoriasis in patients with rheumatoid arthritis receiving anti tumor necrosis factor alpha therapy. Results from the British Society for Rheumatology Biologics Control Centre Consortium. Ann Rheum Dis 2009; 68:209-1.
48. Millonig G, Kern M, Ludwiczek O, et al. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006;12:974-6.
49. Exarchou S, Voulgari P, Markatseli T, et al. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol 2009 Jul 4:1-4. [Epub ahead of print: PMID: 19579151]
50. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86:242-51.
51. Hayat SJ, Uppal SS. Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus. Mod Rheumatol 2007;17:174-7.
52. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-65.
53. de Jong R, Altare F, Haagen IA, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 1998;280:1435-8.
54. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74.
55. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84.